Aduro BioTech, Inc., a clinical stage biotechnology company, today
announced that two posters highlighting clinical trials of the company's
pancreatic cancer and mesothelioma immunotherapies will be presented at
the upcoming American Society of Clinical Oncology (ASCO) to be held in
The presentation will be at the following poster sessions:
Saturday, May 31, 8:00-11:45 a.m.
Sunday, June 1, 8:00-11:00 a.m.
LADD is Aduro's proprietary platform of live-attenuated double-deleted listeria
monocytogenes strains that have been engineered to induce a potent
innate immune response and to express tumor-associated antigens to
induce tumor-specific T cell-mediated immunity. CRS-207 is engineered to
express mesothelin, which is expressed in pancreatic cancer,
mesothelioma and other cancers.
About GVAX and GVAX Pancreas
GVAX Pancreas is one of a family of GVAX vaccines derived human cancer
cell lines which are modified to secrete granulocyte-macrophage
colony-stimulating factor (GM-CSF), an immune-stimulatory cytokine.
Aduro's GVAX portfolio includes vaccines for pancreatic, prostate, colon
and breast cancers as well as multiple myeloma.
About Aduro BioTech, Inc.
Aduro BioTech, Inc. is a private, clinical-stage biotechnology company
focused on immunotherapy for cancer. Aduro has ongoing clinical trials
with its LADD platform in pancreatic cancer, mesothelioma and
glioblastoma and development programs in non-small cell lung cancer,
ovarian cancer and prostate cancer. The company is also developing
clinical candidates using novel small molecules that activate the
intracellular STING receptor, a central mediator of the innate immune
response. For more information, please visit www.adurobiotech.
[ Back To NFVZone's Homepage ]